Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

• Authors: LUDWIG H.; DIMOPOULOS M.A.; MOREAU P.; CHNG W.J.; GOLDSCHMIDT H.; HÁJEK Roman; FACON T.; POUR Luděk; NIESVIZKY R.; ORIOL A.; ROSINOL L.; SUVOROV A.; GAIDANO G.; PIKA T.; WEISEL K.; GORANOVA-MARINOVA V.; PALUMBO A.; GILLENWATER H.H.; MOHAMED N.; AGGARWAL S.; FENG S.B.; JOSHUA D.
• Year of publication: 2017
• Type: Article in Periodical
• Magazine / Source: LEUKEMIA & LYMPHOMA
• MU Faculty or unit: Faculty of Medicine
• Web: http://dx.doi.org/10.1080/10428194.2017.1298755
• Doi: http://dx.doi.org/10.1080/10428194.2017.1298755
• Field: Oncology and hematology
• Keywords: Carfilzomib; dexamethasone; bortezomib
• Description: Article Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.